

# **Treating Traumatic Injury** with Bioengineered **Human Tissues**



MTEC Award: \$6.84M

Sponsor: U.S. Army Medical Research and Development Command

### PROBLEM:

Extremity wounds can be devastating with complex trauma to the vasculature, bone, connective tissues, muscle, and nerves resulting in severely impaired limb function or amputation.

#### SOLUTION:

Humacyte® is pioneering the development of off-the-shelf, universally implantable bioengineered human tissues for patients experiencing blood vessel damage caused by blunt trauma, penetrating injuries, or other catastrophic events.

## **OUTCOME:**

MTEC funding has helped Humacyte® to:


- Develop a commercial-scale manufacturing process to generate clinical grade products
- Demonstrate efficacy in a Phase 2/3 clinical trial in patients with vascular trauma
- Test stability of the product in different environments
- Continue work toward approval for the HAV™ by the U.S. Food and Drug Administration in 2024

\*HAV: Human Acellular Vessel™

# **IMPACT:**

As of April 2023, the bioengineered vessel has been used to:

- Treat 60+ patients in U.S. with vascular trauma
- Treat 18 patients in Ukraine under humanitarian program
- Gather 1K+ patient-years of data around use of the vessel in-human across multiple product opportunities



Follow MTEC on **Social Media** 

with severe limb injuries."



#### For More Information

Lauren Palestrini, PhD Chief Science Officer lauren.palestrini@mtec-sc.org

mtec-sc.org

